Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 15, 2024MAEDICA – a Journal of Clinical MedicineOpen Access

Sylimarin Versus Essential Phospholipids in Metabolic Associated Steatotic Liver Disease (MASLD) – A Prospective Comparative Randomized Trial

View Full Paper
Ask AI
Bookmark
Share

Authors

TMTeodora ManucCPCarmen Monica PredaDIDoina Istrătescu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Manuc et al. (2024) studied this question.

synapsesocial.com/papers/68e73dc3b6db6435876b6bc9https://doi.org/10.26574/maedica.2024.19.1.9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial2024
  2. 2Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial2024 · 30 citations
  3. 3Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial2024 · 2 citations
  4. 4Mediterranean and low-fat diets are equally effective in MASLD resolution at 12 weeks regardless of PNPLA3 genotype: A randomized controlled trial2025 · 5 citations
  5. 5Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis2026